Decoy Therapeutics Files Prospectus For Offering 3.767M Common Shares On Behalf Of Common Shareholders
Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing
Decoy Therapeutics Q1 EPS $(4.18) Misses $(4.08) Estimate
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript
Decoy Therapeutics Regains Nasdaq Compliance
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Decoy Therapeutics shares are trading lower after the company announced a 1-for-12 reverse stock split.
Decoy Therapeutics Announces 1‑For‑12 Reverse Stock Split Effective March 6
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Ladenburg Thalmann Initiates Coverage On Decoy Therapeutics with Buy Rating, Announces Price Target of $2.5
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics shares are trading higher after the company announced it reached global access commitment agreement to focus on the development of a global manufacturing platform for peptide-conjugate antivirals under the Gates Foundation Access agreement.
Decoy Therapeutics Announces Funded Development Of Global Manufacturing Platform For Peptide‑Conjugate Antivirals Under Gates Foundation Access Agreement
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Salarius: Q2 Earnings Snapshot
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.